What guidance did ProPhase Labs's management provide for the next earnings period?

What is the revenue and EPS growth rate for ProPhase Labs year over year?

What were the key takeaways from ProPhase Labs's earnings call?

Did ProPhase Labs beat or miss consensus estimates last quarter?

What does ProPhase Labs do and what are its main business segments?

What is the market's earnings forecast for ProPhase Labs next quarter?

What factors drove the changes in ProPhase Labs's revenue and profit?

What were the key takeaways from ProPhase Labs’s earnings call?

- **Crown Medical Cash Inflow**: $50M+ net expected from COVID testing settlements, driving strategic flexibility.
- **BE-Smart Test Potential**: FDA-cleared with $7B-$14B market, seeking partnerships for rapid growth.
- **Nebula Profitability**: Subscription model now profitable, poised for expansion.
- **Proxy Vote Urgency**: Critical for NASDAQ compliance and strategic initiatives.
- **Undervalued Assets**: $12M market cap vs. $1B+ potential for esophageal cancer test alone.

**【CEO Summary Section】**
- **Crown Medical Collections Progress**: Legal hurdles cleared; $50M+ net cash inflow expected from insurance settlements. Special counsel appointed, with expedited litigation to drive quick resolutions.
- **BE-Smart Esophageal Cancer Test**: FDA-cleared as LDT, with potential for $7B-$14B market. Seeking partnerships/joint ventures for rapid commercialization and high-margin revenue.
- **Nebula Genomics Restructuring**: Transitioned to subscription model, now profitable with 95%+ renewal margins. Growth plans contingent on future cash flow.
- **Proxy Vote Criticality**: Essential for maintaining NASDAQ compliance and pursuing strategic initiatives. Reverse stock split consideration to avoid delisting, with potential positive stock price impact.
- **Market Disconnect**: Current $12M market cap undervalues assets; esophageal cancer test alone could justify 10x+ increase in market value within 18 months.

**【Q&A Key Highlights】**
- **Strategic Deal Exploration**: Actively pursuing biotech partnerships and potential reverse crypto strategy if cash flow permits. Recent interest from industry leaders for esophageal cancer test collaboration.
- **Cash Flow and Buybacks**: Future Crown Medical proceeds may fund share buybacks, with CEO history of aggressive buybacks in prior turnarounds.
- **Financial Position**: Tight on cash but exploring debt/equity options. Emphasis on maintaining flexibility for strategic moves.
- **Short-Term Challenges**: Short selling pressure and cash constraints driving stock price weakness, expected to resolve with Crown Medical inflows.


ProPhase Labs, Inc. (PRPH) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

PRPH

PRPH fundamentals

You can ask Aime